← back to search

Noushin Niknafs

Johns Hopkins University · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, and Immunotherapy and Immune Responses.
h-index
34
citations
9,995
works
285
NIH funding
primary concept
email

Recent publications

Abstract 7424: Longitudinal and spatial heterogeneity of intra-tumoral TCR repertoires during immunotherapy in metastatic cancers
Cancer Research 2026cited by 0position: middledoi
Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes
Cancer Discovery 2025cited by 10position: middledoi
3D genomic mapping reveals multifocality of human pancreatic precancers
Nature 2024cited by 126position: middledoi
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Cancer Discovery 2024cited by 50position: middledoi
Persistent mutation burden drives sustained anti-tumor immune responses
Nature Medicine 2023cited by 140position: firstdoi
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Nature Medicine 2023cited by 137position: middledoi
Detecting Liver Cancer Using Cell-Free DNA Fragmentomes
Cancer Discovery 2022cited by 149position: middledoi
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
Journal for ImmunoTherapy of Cancer 2022cited by 132position: middledoi
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Nature Communications 2021cited by 452position: middledoi
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Nature Medicine 2021cited by 125position: middledoi
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Nature Cancer 2020cited by 207position: middledoi
Genomic characterization of malignant progression in neoplastic pancreatic cysts
Nature Communications 2020cited by 134position: middledoi
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
Cell Reports Medicine 2020cited by 78position: middledoi
Genome-wide cell-free DNA fragmentation in patients with cancer
Nature 2019cited by 1,440position: middledoi
Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations
Gastroenterology 2019cited by 130position: middledoi
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
Annals of Oncology 2018cited by 582position: middledoi
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Cancer Research 2018cited by 310position: middledoi
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Oncotarget 2018cited by 157position: middledoi
High grade serous ovarian carcinomas originate in the fallopian tube
Nature Communications 2017cited by 752position: middledoi
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Cell 2017cited by 518position: middledoi
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Cancer Discovery 2016cited by 893position: middledoi
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure
Cancer Research 2016cited by 140position: middledoi
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma
Cancer Prevention Research 2016cited by 96position: middledoi
The genomic landscape of response to EGFR blockade in colorectal cancer
Nature 2015cited by 492position: middledoi
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
Gastroenterology 2015cited by 456position: middledoi
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer
Cancer Discovery 2015cited by 365position: middledoi
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Nature Genetics 2013cited by 708position: middledoi
CRAVAT: cancer-related analysis of variants toolkit
Bioinformatics 2013cited by 181position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rachel Karchin · University of Baltimore6 papers (2013–2023)Victor E. Velculescu · Sidney Kimmel Cancer Center4 papers (2017–2023) · 4 papers (2020–2026)Valsamo Anagnostou · Cornell University4 papers (2017–2023)Julie R. Brahmer · Bloomberg (United States)3 papers (2023–2026)Robert B. Scharpf · Johns Hopkins University3 papers (2019–2022)Mark Sausen · Human Genome Sciences (United States)2 papers (2016–2023)Benjamin Levy · Israel Cancer Association2 papers (2023–2023)Collin Tokheim · Johns Hopkins University2 papers (2016–2016)Laura D. Wood · Wellcome Sanger Institute2 papers (2016–2019)David L. Masica · AbbVie (United States)2 papers (2016–2019)Xiaoshan M. Shao · Johns Hopkins Medicine2 papers (2020–2023)Christine L. Hann · Johns Hopkins University2 papers (2023–2026)Rick Kim · University of California, Santa Cruz2 papers (2013–2016)Joseph C. Murray · Georgetown University2 papers (2020–2023)Daniel C. Bruhm · Johns Hopkins University2 papers (2020–2022)Drew M. Pardoll · Bloomberg (United States)2 papers (2020–2023)Zineb Belcaid · Erasmus MC2 papers (2020–2023)Julie E. Stein · Sidney Kimmel Comprehensive Cancer Center1 papers (2020–2020)Luigi Marchionni · Cornell University1 papers (2016–2016)